Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium's strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium's headquarters a ...

Core Viewpoint - Collegium Pharmaceutical, Inc. has initiated an Accelerated Share Repurchase (ASR) agreement to repurchase $25 million of its common stock as part of a broader $150 million share repurchase program, reflecting a strategic approach to capital allocation while driving revenue growth and returning capital to shareholders [1][2]. Group 1: Financial Performance - In the first quarter of 2025, Collegium reported a 23% year-over-year revenue growth, attributed to strong sales from its pain management portfolio and significant contributions from its ADHD medication, Jornay PM® [2]. - The ASR agreement will initially deliver 692,281 shares to Collegium, based on a closing stock price of $28.89 on May 9, 2025, which represents approximately 80% of the total shares expected to be repurchased [2]. Group 2: Strategic Initiatives - The Board of Directors authorized the $25 million ASR as part of a disciplined capital allocation strategy aimed at sustaining revenue growth while also returning capital to shareholders [2]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as a key growth driver and investing in business development while managing debt and share repurchases [2][3]. Group 3: Company Overview - Collegium Pharmaceutical is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a strong portfolio in pain management and a recent entry into neuropsychiatry through the acquisition of Jornay PM [3].

Q1 2025 Earnings Report May 8, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events ...

Financial Performance - Collegium Pharmaceutical reported Q1 2025 net revenue of $177.8 million, representing a 23% increase year-over-year from $144.9 million in Q1 2024 [9][24] - The company generated $149.2 million from its pain portfolio, up 3% year-over-year, with all three core products showing revenue growth [10][24] - Net revenue from Jornay PM reached $28.5 million in Q1 2025, with a year-over-year prescription growth of 24% [6][9] Strategic Initiatives - The company completed an expansion of its Jornay PM field force, adding 55 new sales representatives, bringing the total to approximately 180 [3][6] - Collegium reaffirmed its full-year 2025 guidance, projecting product revenues between $735 million and $750 million [8] - The board authorized a $25 million accelerated share repurchase program to enhance shareholder value [3][10] Cash Position and Debt Management - As of the end of Q1 2025, Collegium had cash, cash equivalents, and marketable securities totaling $197.8 million, an increase from $162.8 million at the end of 2024 [3][26] - The company paid down an additional $16.1 million in debt during the quarter [3][10] Leadership and Corporate Updates - Collegium made significant additions to its leadership team and board of directors, including the appointment of new executive leaders and board members [10][10] - The company was recognized as a Top Workplace by USA TODAY and a Best Places to Work honoree by the Boston Business Journal [10][10]